Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Lp-PLA2-IN-12 (compound 19), an Lp-PLA2 inhibitor, is utilized in researching neurodegenerative diseases including Alzheimer's disease (AD), glaucoma, age-related macular degeneration (AMD), and cardiovascular conditions such as atherosclerosis [1].
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
25 mg | 6-8 weeks | $ 1,520.00 | |
50 mg | 6-8 weeks | $ 1,980.00 | |
100 mg | 6-8 weeks | $ 2,500.00 |
Description | Lp-PLA2-IN-12 (compound 19), an Lp-PLA2 inhibitor, is utilized in researching neurodegenerative diseases including Alzheimer's disease (AD), glaucoma, age-related macular degeneration (AMD), and cardiovascular conditions such as atherosclerosis [1]. |
Molecular Weight | 467.47 |
Formula | C24H23F2N5O3 |
CAS No. | 2637485-14-2 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Lp-PLA2-IN-12 2637485-14-2 Metabolism Phospholipase inhibitor inhibit